1. Home
  2. ENOV vs HRMY Comparison

ENOV vs HRMY Comparison

Compare ENOV & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enovis Corporation

ENOV

Enovis Corporation

HOLD

Current Price

$27.24

Market Cap

1.7B

Sector

Industrials

ML Signal

HOLD

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$37.66

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENOV
HRMY
Founded
1995
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Fluid Controls
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
ENOV
HRMY
Price
$27.24
$37.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
9
Target Price
$49.14
$51.33
AVG Volume (30 Days)
854.1K
772.8K
Earning Date
11-06-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.44
EPS
N/A
3.17
Revenue
$2,233,266,000.00
$825,944,000.00
Revenue This Year
$9.27
$23.11
Revenue Next Year
$4.56
$16.15
P/E Ratio
N/A
$12.24
Revenue Growth
11.57
21.13
52 Week Low
$25.47
$25.52
52 Week High
$49.38
$40.93

Technical Indicators

Market Signals
Indicator
ENOV
HRMY
Relative Strength Index (RSI) 43.46 57.18
Support Level $25.52 $38.12
Resistance Level $28.02 $40.87
Average True Range (ATR) 1.28 1.35
MACD -0.03 -0.22
Stochastic Oscillator 31.79 42.28

Price Performance

Historical Comparison
ENOV
HRMY

About ENOV Enovis Corporation

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: